Cited 1 times in
Antitumor Effect of Low-Dose of Rapamycin in a Transgenic Mouse Model of Liver Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김명수 | - |
dc.contributor.author | 주동진 | - |
dc.date.accessioned | 2022-12-22T05:16:13Z | - |
dc.date.available | 2022-12-22T05:16:13Z | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192350 | - |
dc.description.abstract | Purpose: We investigate whether low-dose rapamycin is effective in preventing hepatocellular carcinoma (HCC) growth and treating HCC after tumor development in transgenic mice. Materials and methods: We established transgenic mice with HCC induced by activated HrasG12V and p53 suppression. Transgenic mice were randomly assigned to five experimental groups: negative control, positive control, tacrolimus only, rapamycin only, and tacrolimus plus rapamycin. The mice were further divided into two groups according to time to commencement of immunosuppressant treatment: de novo treatment and post-tumor development. Results: In the de novo treatment group, marked suppression of tumor growth was observed in the rapamycin only group. In the post-tumor development group, the rapamycin only group displayed no significant suppression of tumor growth, compared to the positive control group. In T lymphocyte subset analysis, the numbers of CD4+ effector T cells and CD4+ regulatory T cells were significantly lower in the positive control, tacrolimus only, and tacrolimus plus rapamycin groups than the negative control group. Immunohistochemical analysis revealed significantly higher expression of phosphorylated-mTOR, 4E-BP1, and S6K1 in the positive control group than in the rapamycin only group. Conclusion: Low-dose rapamycin might be effective to prevent HCC growth, but may be ineffective as a treatment option after HCC development. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / drug therapy | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / genetics | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / metabolism | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | Liver Neoplasms* / drug therapy | - |
dc.subject.MESH | Liver Neoplasms* / genetics | - |
dc.subject.MESH | Liver Neoplasms* / metabolism | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Transgenic | - |
dc.subject.MESH | Sirolimus / therapeutic use | - |
dc.subject.MESH | Tacrolimus / pharmacology | - |
dc.subject.MESH | Tacrolimus / therapeutic use | - |
dc.title | Antitumor Effect of Low-Dose of Rapamycin in a Transgenic Mouse Model of Liver Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Hyung Soon Lee | - |
dc.contributor.googleauthor | Joon Ye Kim | - |
dc.contributor.googleauthor | Simon Weonsang Ro | - |
dc.contributor.googleauthor | Myoung Soo Kim | - |
dc.contributor.googleauthor | Haeryoung Kim | - |
dc.contributor.googleauthor | Dong Jin Joo | - |
dc.identifier.doi | 10.3349/ymj.2022.0247 | - |
dc.contributor.localId | A00424 | - |
dc.contributor.localId | A03948 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 36303309 | - |
dc.subject.keyword | Liver | - |
dc.subject.keyword | carcinoma | - |
dc.subject.keyword | hepatocellular | - |
dc.subject.keyword | mice | - |
dc.subject.keyword | sirolimus | - |
dc.subject.keyword | transgenic | - |
dc.contributor.alternativeName | Kim, Myoung Soo | - |
dc.contributor.affiliatedAuthor | 김명수 | - |
dc.contributor.affiliatedAuthor | 주동진 | - |
dc.citation.volume | 63 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1007 | - |
dc.citation.endPage | 1015 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.63(11) : 1007-1015, 2022-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.